Literature DB >> 29999412

HIV-1 Infection and Type 1 Interferon: Navigating Through Uncertain Waters.

Sho Sugawara1, David L Thomas1, Ashwin Balagopal1.   

Abstract

HIV-1 remains a chronic viral infection of global health importance. Although HIV-1 replication can be controlled by antiretroviral therapy (ART), there is no cure due to persistence of a long-lived latent reservoir. In addition, people living with HIV-1 who are taking ART still bear signatures of persistent immune activation that include continued type 1 interferon (IFN) signaling. Paradoxically, type 1 IFN exerts a limited role on the control of chronic HIV-1. Indeed, recent reports from humanized mice suggest that type 1 IFN may partly maintain the latent reservoir. In this review, we discuss the molecular interactions between HIV-1 and the type 1 IFN signaling pathway, and examine the efficacy of type 1 IFNs in vivo. We also explore whether limited type 1 IFN manipulation may have a therapeutic role.

Entities:  

Keywords:  HIV-1 pathogenesis; immune activation; persistent latent reservoir; type 1 interferon

Mesh:

Substances:

Year:  2018        PMID: 29999412      PMCID: PMC6343185          DOI: 10.1089/AID.2018.0161

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  88 in total

Review 1.  Modulation of T-cell function by type I interferon.

Authors:  David F Tough
Journal:  Immunol Cell Biol       Date:  2012-03-06       Impact factor: 5.126

2.  HIV Vpu Interferes with NF-κB Activity but Not with Interferon Regulatory Factor 3.

Authors:  Lara Manganaro; Elisa de Castro; Ana M Maestre; Kevin Olivieri; Adolfo García-Sastre; Ana Fernandez-Sesma; Viviana Simon
Journal:  J Virol       Date:  2015-07-15       Impact factor: 5.103

3.  Alpha interferon and HIV infection cause activation of human T cells in NSG-BLT mice.

Authors:  Brian R Long; Cheryl A Stoddart
Journal:  J Virol       Date:  2012-01-11       Impact factor: 5.103

4.  Hepatitis C virus blocks interferon effector function by inducing protein kinase R phosphorylation.

Authors:  Urtzi Garaigorta; Francis V Chisari
Journal:  Cell Host Microbe       Date:  2009-12-17       Impact factor: 21.023

5.  Effects of type I interferons on Friend retrovirus infection.

Authors:  Nicole Gerlach; Simone Schimmer; Siegfried Weiss; Ulrich Kalinke; Ulf Dittmer
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

6.  Chronic CD4+ T-cell activation and depletion in human immunodeficiency virus type 1 infection: type I interferon-mediated disruption of T-cell dynamics.

Authors:  Ahmad R Sedaghat; Jennifer German; Tanya M Teslovich; Joseph Cofrancesco; Chunfa C Jie; C Conover Talbot; Robert F Siliciano
Journal:  J Virol       Date:  2007-12-12       Impact factor: 5.103

7.  Relative resistance of HIV-1 founder viruses to control by interferon-alpha.

Authors:  Angharad E Fenton-May; Oliver Dibben; Tanja Emmerich; Haitao Ding; Katja Pfafferott; Marlen M Aasa-Chapman; Pierre Pellegrino; Ian Williams; Myron S Cohen; Feng Gao; George M Shaw; Beatrice H Hahn; Christina Ochsenbauer; John C Kappes; Persephone Borrow
Journal:  Retrovirology       Date:  2013-12-03       Impact factor: 4.602

8.  Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection.

Authors:  Caroline Goujon; Olivier Moncorgé; Hélène Bauby; Tomas Doyle; Christopher C Ward; Torsten Schaller; Stéphane Hué; Wendy S Barclay; Reiner Schulz; Michael H Malim
Journal:  Nature       Date:  2013-09-18       Impact factor: 49.962

9.  Type I interferon responses are impaired in latently HIV infected cells.

Authors:  Nischal Ranganath; Teslin S Sandstrom; Saleh Fadel; Sandra C Côté; Jonathan B Angel
Journal:  Retrovirology       Date:  2016-09-09       Impact factor: 4.602

10.  Defective proviruses rapidly accumulate during acute HIV-1 infection.

Authors:  Katherine M Bruner; Alexandra J Murray; Ross A Pollack; Mary G Soliman; Sarah B Laskey; Adam A Capoferri; Jun Lai; Matthew C Strain; Steven M Lada; Rebecca Hoh; Ya-Chi Ho; Douglas D Richman; Steven G Deeks; Janet D Siliciano; Robert F Siliciano
Journal:  Nat Med       Date:  2016-08-08       Impact factor: 53.440

View more
  7 in total

Review 1.  Type I Interferons in NeuroHIV.

Authors:  Victoria E Thaney; Marcus Kaul
Journal:  Viral Immunol       Date:  2018-09-27       Impact factor: 2.257

2.  Interferon-α alters host glycosylation machinery during treated HIV infection.

Authors:  Leila B Giron; Florent Colomb; Emmanouil Papasavvas; Livio Azzoni; Xiangfan Yin; Matthew Fair; Alitzel Anzurez; Mohammad Damra; Karam Mounzer; Jay R Kostman; Pablo Tebas; Una O'Doherty; Hiroaki Tateno; Qin Liu; Michael R Betts; Luis J Montaner; Mohamed Abdel-Mohsen
Journal:  EBioMedicine       Date:  2020-08-19       Impact factor: 8.143

3.  People with HIV-1 demonstrate type 1 interferon refractoriness associated with upregulated USP18.

Authors:  Sho Sugawara; Ramy El-Diwany; Laura K Cohen; Kimberly E Rousseau; Christopher Y K Williams; Rebecca T Veenhuis; Shruti H Mehta; Joel N Blankson; David L Thomas; Andrea L Cox; Ashwin Balagopal
Journal:  J Virol       Date:  2021-03-03       Impact factor: 5.103

4.  Single-cell glycomics analysis by CyTOF-Lec reveals glycan features defining cells differentially susceptible to HIV.

Authors:  Tongcui Ma; Matthew McGregor; Leila Giron; Guorui Xie; Ashley F George; Mohamed Abdel-Mohsen; Nadia R Roan
Journal:  Elife       Date:  2022-07-05       Impact factor: 8.713

5.  Differential Inhibition of HIV Replication by the 12 Interferon Alpha Subtypes.

Authors:  Armando Espinosa Ortiz; Olivia Blake; Alexandra Tauzin; Calaiselvy Soundaramourty; Charles Joly-Beauparlant; Alexandre Nicolas; Arnaud Droit; Jacques Dutrieux; Jérôme Estaquier; Fabrizio Mammano
Journal:  J Virol       Date:  2021-07-12       Impact factor: 5.103

Review 6.  Role of Complement Receptors (CRs) on DCs in Anti-HIV-1 Immunity.

Authors:  Wilfried Posch; Marta Bermejo-Jambrina; Cornelia Lass-Flörl; Doris Wilflingseder
Journal:  Front Immunol       Date:  2020-11-03       Impact factor: 7.561

7.  Distinct Molecular Signatures of Aging in Healthy and HIV-Infected Individuals.

Authors:  Stefano Rinaldi; Suresh Pallikkuth; Lesley De Armas; Brian Richardson; Li Pan; Rajendra Pahwa; Sion Williams; Mark Cameron; Savita Pahwa
Journal:  J Acquir Immune Defic Syndr       Date:  2022-02-01       Impact factor: 3.771

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.